GenVec — Merger or Acquisition (July 2003)
35 slides from GenVec's merger presentation, Jul 30, 2003
Slide 1: GenVec-Diacrin Proposed Merger
GENVEC GenVec-Diacrin Proposed Merger
Slide 2: Forward-Looking Statements
Forward-Looking Statements The presentations made during this meeting and other statements by GenVec may include forward- looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the pending merger with Diacrin, product candidates under development, futur
Slide 3: Merger: Additional Information
Merger: Additional Information GenVec has filed a registration statement with the SEC under the Securities Act of 1933, which contains a joint proxy statement/prospectus of GenVVec and Diacrin with respect to the merger and the parties also have filed other relevant materials with the SEC. INVESTORS
Slide 4: Diacrin
<3 DIACRIN
Slide 5: GenVec/Diacrin Advantages
a GENES GenVec/Diacrin Advantages © $45M in cash and investments at closing + $10M revenues expected in 2003 * Cash burn of $15 to $18M per year ¢ Multiple products in clinical testing (Phase 1 and Phase 2) ¢ Government-funded vaccine collaborations ¢ Internal manufacturing capability ¢ Differentiat
Slide 6: Experienced Management Team
a GENES Experienced Management Team Paul Fischer, Ph.D. - President and CEO, GenVec Jeff Church — CFO, GenVec Michael Egan — COO, Diacrin Dave Robinson — VP Commercial Development, GenVec Rick King, Ph.D. — VP Research, GenVec Jon Dinsmore, Ph.D. - Sr. Dir. Transplantation Research, Diacrin Paul Kes
Slide 7: New Board of Directors
New Board of Directors Paul Fischer, Ph.D. — President and CEO of GenVec since 1995, formerly with Oncologix, Inc., Pfizer, Inc. and University of Wisconsin ‘Thomas H. Fraser, Ph.D. - Board Chairman — former CEO and Director of Diacrin, formerly with Repligen. Corporation and Upjoln Corporation Barb
Slide 8: GenVec/Diacrin Business Objectives
a GENES GenVec/Diacrin Business Objectives ¢ Commercialize TNFerade™ for cancer in North America, targeting end of 2006 * Grow the cash-flow positive vaccine program and expand internal manufacturing at Diacrin’s Charlestown facility « Advance our remaining therapeutic portfolio through strategic al
Slide 9: Commercialization Goals
Commercialization Goals ae TNFerade™ - Esophageal | Pivotal Trial(s) Clinical Supplies Co/Co Royalties Oncology Pancreatic New Indication(s) (Targeted Genetics) 2006 Launch Right to Rectal Launch Product from Manufacture Diacrin Facility
Slide 10: Commercialization Goals
Commercialization Goals TNFerade™ - Esophageal | Pivotal Trial(s) Clinical Supplies Co/Co Royalties Oncology Pancreatic New Indication(s) (Targeted Genetics) 2006 Launch Right to Rectal Launch Product from Manufacture Diacrin Facility Vaccine Program | Funded Research | Clinical Trials | ProcessDeve
Slide 11: Commercialization Goals
Commercialization Goals TNFerade™ - Esophageal | Pivotal Trial(s) Clinical Supplies Co/Co Royalties Oncology Pancreatic New Indication(s) (Targeted Genetics) 2006 Launch Right to Rectal Launch Product from Manufacture Diacrin Facility Vaccine Program | Funded Research | Clinical Trials | ProcessDeve
Slide 12: Commercialization Goals
Commercialization Goals TNFerade™ - Esophageal | Pivotal Trial(s) Clinical Supplies Co/Co Royalties Oncology Pancreatic New Indication(s) (Targeted Genetics) 2006 Launch Right to Rectal Launch Product from Manufacture Diacrin Facility Vaccine Program | Funded Research | Clinical Trials | ProcessDeve
Slide 13: Commercialization Goals
Commercialization Goals TNFerade™ - Esophageal | Pivotal Trial(s) Clinical Supplies Co/Co Royalties Oncology Pancreatic New Indication(s) (Targeted Genetics) 2006 Launch Right to Rectal Launch Product from Manufacture Diacrin Facility Vaccine Program | Funded Research | Clinical Trials | ProcessDeve
Slide 14: Technology Platform Advantages
a GENES Technology Platform Advantages * Gene-based protein delivery — Applicable for therapeutic products — Applicable for vaccine development — Common manufacturing processes for our products — Localized, low-dose drug delivery * Cell-based therapeutics — Applicable to severe heart disease — Abili
Slide 15: Technology for Therapeutics and Vaccines
a CEN ES Technology for Therapeutics and Vaccines Adenovector Insert DNA Insert DNA for therapeutic for antigenic protein protein Therapeutic Candidate Vaccine Candidate Locally Administered
Slide 16: TNFerade for Oncology
a GENES TNFerade™ for Oncology Intratumoral delivery of INFa.to improve safety and effectiveness Use with standard of care ~ Radiation — Chemotherapy Ongoing Phase 2 studies = Locally advanced pancreatic cancer — Non-metastatic esophageal cancer Broad potential use for other cancers — Rectal, head a
Slide 17: TNFerade Development Summary
a GENES TNFerade™ Development Summary * Core Objectives — Obtain commercial approval by the end of 2006 — Identify additional indications — Target broader use with standard cancer therapy * Core Strategy = Identify possible indications for rapid approval, determine dosing regimen and move forward wi
Slide 18: 2003 Objectives for TNFerade
a GENES 2003 Objectives for TNFerade + Establish dosing regimen and indications for pivotal trials — Pancreatic - dose escalation complete; trial design ongoing; awaiting efficacy data — Esophageal — dose escalation ongoing — Palliation — define target patient population and trial design ongoing * C
Slide 19: TNFerade in Combination with Radiation Therapy: Phase 1 Summary
TNFerade™ in Combination with coale Radiation Therapy: Ph 1 Summary Tumor Types Partial Responding: Responses + breast + rectal + melanoma + lung * pancreas + hepatocellular * sarcoma +head/neck + colon + bladder + adrenal + billiary Minor Responses Complete Responses Tumor shrinkage demonstrated in
Slide 20: Clinical Response to TNFerade and Radiation Therapy
Clinical Response to TNEerade"™ ail linical Response to TNFerade™ and Radiation Therapy Radiation Only Radiation Only a Tea TNFerade™ + =e Radiation End of treatment Pre-treatment metastatic breast cancer 3 months post-treatment Tumor eradicated
Slide 21: Phase 1 Study in Soft Tissue Sarcoma
a GENES Phase 1 Study in Soft Tissue Sarcoma * Well tolerated with no dose limiting toxicities ¢ TNFerade™ plus radiation resulted in an overall objective tumor response rate of 85% (11 of 13 patients) * 100% objective response rate at highest dose of TNFerade™ (6/6) * Complete response in 2 of 13 p
Slide 22: Pancreatic Cancer: Preliminary Results
a GENES Pancreatic Cancer: Preliminary Results ¢ TNFerade™ dose escalation phase ongoing ¢ First 17 patients from initial two cohorts (4 x 10°, 4x 10'° pu) ¢ Repeated intratumoral injections of TNFerade™ combined. with continuous infusion 5-FU and radiation were well tolerated. ¢ TNFerade™ administe
Slide 23: Ongoing Trial in Esophageal Cancer
a GENES Ongoing Trial in Esophageal Cancer ¢ TNFerade™ dose escalation phase ongoing ¢ Establish dose when used in combination with radiation therapy, fluorouracil and cis-platinum Dose Expected Status patients 4x108 pu 6 4/6 4x10° pu 6 0/6 4x10" pu 6 0/6
Slide 24: 2004 Objectives for TNFerade
a GENES 2004 Objectives for TNFerade ¢ Initiate at least one randomized, controlled pivotal trial in esophageal cancer, pancreatic cancer or for palliation ¢ Initiate additional Phase 1/2 studies to expand potential uses ¢ Establish TNFerade™ production capability at Diacrin facility
Slide 25: BIOBYPASS for Coronary Artery Disease (CAD)
BIOBYPASS. for Hates Coronary Artery Disease (CAD) * Narrowing of coronary arteries results in poor blood flow ¢ BIOBYPASS® is designed to stimulate new blood vessel formation, and improve blood flow * Positive Phase 2 data presented at November 2002 AHA Annual Meeting
Slide 26: Randomized, Controlled Phase 2 Study
Randomized, Controlled Phase 2 Study * Severe heart disease (“no option”) patients — BIOBYPASS® administered directly into the heart muscle in a surgical procedure * Significant clinical benefits — Exercised longer on treadmill — Exercised longer before EKG changes — Improved quality of life * Well
Slide 27: Improved Ability to Exercise
a GENES Improved Ability to Exercise Time to Chest Pain Total Exercise Duration p=0.006 p=0.002 p=0.011 p=0.014 20 3 —] BIOBYPASS® ef Control = S 15 o £ 5) 40 Fy & ao 5 05 € _ 2 J £00 —— + cS £ oO as Week 12 Week 26 Mean + SEM Week 12 Week 26 feel feel Weeks Post Treatment
Slide 28: Development of BIOBYPASS
a GENES Development of BIOBYPASS® « Feasibility of catheter-based delivery demonstrated * Form collaboration to advance clinical development * Meet with the FDA on trial design « Initiate randomized, placebo-controlled study using injection catheter
Slide 29: Age-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) * Wet AMD - growth of tiny blood vessels under the retina that leak fluid, distorting vision and causing scarring. ¢ Over 200,000 Americans have wet AMD ¢ Strong commercial interest in new fos treatments for AMD
Slide 30: AdPEDF to Treat AMD
a GENES AdPEDF to Treat AMD * Multiple modes of action — Inhibits new blood vessel formation. — Causes abnormal blood vessels to regress — Stabilizes photoreceptors « Effective and well tolerated in preclinical studies * Multiple routes of administration
Slide 31: AdPEDF Development Overview
a GENES AdPEDF Development Overview « Phase | trial in patients with severe age-related (wet) macular degeneration ongoing — Dose escalation trial design — Accrual in first four cohorts completed. * Phase 2 trial to assess efficacy and safety in AMD patients being designed for possible initiation in
Slide 32: Myoblasts for Cardiac Repair
a GENES Myoblasts for Cardiac Repair * Use patient’s own cells to repair the damage caused by myocardial infarctions ¢ Effective in animal models * Phase | testing ongoing to evaluate safety and feasibility * Extended clinical evaluation to assess improvement in functional parameters
Slide 33: Proposed Merger of GenVec and Diacrin
Proposed Merger of GenVec and Diacrin . + Expected closing 3Q03 subject to shareholder approval + Announced April 15, 2003 Combined Company + Develop TNFerade™ + Expand vaccine business + Form product partnerships + Operating horizon into 2006 Diacrin +$43 million in cash as of 3/31/03 + Product can
Slide 34: GenVec — Post Merger Financial Projections
a GENES GenVec — Post Merger Financial Projections * Revenue from funded R&D contracts at $10M per year * Cash burn of $15 to $18M per year * Operating horizon extended well into 2006 without additional equity financing * Supplement internal product development efforts with strategic alliances/partn
Slide 35: Searchable text section of graphics shown above
Searchable text section of graphics shown above Filed by GenVec, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject company: GenVec, Inc Commission File No. 333-105320 This filing relates to a proposed